Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications

In short

This is a Research and Innovation Action under Horizon Europe. The budget is €38 million for about 4 grants of €8 million to €10 million each. Deadline: 17 February 2027.

What the call wants to achieve

• Patients benefit from decreased incidence of Adverse Drug Reactions (ADRs) caused by the administration of multiple medications (three or more medicinal products [1] ) and enhanced health outcomes by ensuring safer and more effective use of medication.
• Healthcare professionals can adopt adverse drug reactions prevention and reduction strategies to integrate genetic and other biomarker information into clinical decision-making to optimise the use of medication, especially in situations of comorbidities.
• Healthcare systems benefit from cost savings thanks to reduced hospital admissions and other costs associated with ADRs related to the intake of multiple medicines.
• Clinical and regulatory guidelines and policies for medication management in case of multiple medications can be revised supported by robust evidence.

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0, summarised. The official call text and its annexes decide eligibility, budget and deadlines.

Similar calls